Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
NCCN Conference Highlights
Updates to Screening and Surveillance Recommendations for Colorectal Cancer
By
Wayne Kuznar
NCCN Conference Highlights
June 2022, Vol 13, No 3
Updates to the screening guidelines for colorectal cancer (CRC) from the National Comprehensive Cancer Network (NCCN) include lowering the initial screening age for average-risk individuals and second- and third-degree family members with CRC, as well as an extension in the interval for surveillance colonoscopy for low-risk individuals.
Read Article
The Role of Telehealth in the Delivery of Cancer Care: Exploring Ongoing Opportunities and Challenges
By
Wayne Kuznar
NCCN Conference Highlights
June 2022, Vol 13, No 3
Telehealth is playing a larger role in the delivery of cancer care, but there is more work that needs to be done to permanently increase access, according to a panel of experts during a plenary session at the National Comprehensive Cancer Network (NCCN) 2022 Annual Conference.
Read Article
Updated NCCN Guideline for Neuroendocrine Tumors and Carcinoid Syndrome Features New Therapies
By
Wayne Kuznar
NCCN Conference Highlights
,
NCCN Guidelines
,
Policies & Guidelines
June 2017, Vol 8, No 3
Orlando, FL—Somatostatin analogs have multiple roles in the treatment of neuroendocrine tumors (NETs), including the management of symptoms of hormone hypersecretion and, more recently, slowing tumor progression.
Read Article
NCCN Lung Cancer Guidelines: Combinations May Be the Future of Immunotherapy
By
Wayne Kuznar
Immunotherapy
,
NCCN Conference Highlights
,
Personalized Medicine
June 2017, Vol 8, No 3
Orlando, FL—Immunotherapy is now an established option for patients with non–small-cell lung cancer (NSCLC) in the second-line setting and in selected patients in the first-line setting.
Read Article
Multigene Panel Tests in Breast and Ovarian Cancers
NCCN Conference Highlights
June 2017, Vol 8, No 3
Orlando, FL—The National Comprehensive Cancer Network (NCCN) has provided guidance for the clinical management of genetic mutation carriers who are identified using multigene panels without endorsing the routine use of these tests outside of research and/or intensive counseling on the risks and benefits of their use.
Read Article
NCCN Recommends Biomarker Testing for All Patients with Newly Diagnosed NSCLC
By
Wayne Kuznar
NCCN Conference Highlights
June 2017, Vol 8, No 3
Orlando, FL—Molecular analysis and PD ligand 1 (PD-L1) testing for patients with non–small-cell lung cancer (NSCLC) are critically important. Optimally, multiple biomarker testing should be done at diagnosis, but it also has value before choosing therapy for second-line or later.
Read Article
Genomic Instability Score Predicts Survival in Patients with Ovarian Cancer
NCCN Conference Highlights
May 2016, Vol 7, No 4
A higher score on a composite index of homologous recombination deficiency (HRD), indicating genomic instability, correlated with improved progression-free survival (PFS) and overall survival (OS) in patients with ovarian cancer who have received platinum-containing chemotherapy, according to results presented at the 2016 Society of Gynecologic Oncology annual meeting.
Read Article
NCCN Evidence Blocks Help Frame Value-Based Decisions for Systemic Therapies
By
Wayne Kuznar
NCCN Conference Highlights
May 2016, Vol 7, No 4
The evidence blocks were incorporated into the National Comprehensive Cancer Network (NCCN) clinical practice guidelines late last year and act as a visual representation of 5 key measures related to specific recommendations.
Read Article
Immunotherapy Takes Center Stage in the Updated NCCN Guideline for Advanced Melanoma
By
Wayne Kuznar
NCCN Conference Highlights
May 2016, Vol 7, No 4
The updated National Comprehensive Cancer Network (NCCN) guideline (version 2.2016) for the management of advanced melanoma reflects the increasing role of immune checkpoint inhibitors and targeted agents, as more data establish their superior efficacy over traditional chemotherapy.
Read Article
Updated NCCN Multiple Myeloma Guideline Expands Patient Eligibility and Therapeutic Options
By
Wayne Kuznar
NCCN Conference Highlights
May 2016, Vol 7, No 4
The population of patients with multiple myeloma who are eligible for therapy has been expanded to include asymptomatic patients with certain features, according to the most recent National Comprehensive Cancer Network (NCCN) guideline (version 3.2016).
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma